Calgary, Alberta--(Newsfile Corp. - January 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is proud to announce its participation in two highly anticipated Puerto Rico Investor Summits:
Sequire Investor Summit: January 22-23 at the Condado Vanderbilt Hotel.
CytoImmune-hosted Event: January 24 at CytoImmune's state-of-the-art facility in San Juan, Puerto Rico.
Thomas Smeenk, President & CEO of Hemostemix, will deliver an engaging presentation highlighting the Company's groundbreaking ACP-01 therapy, global scale-up strategy, and collaborations that are creating economic opportunities for clinicians.
Why This Matters: Key Highlights of Hemostemix's Strategy
1. Revolutionizing Therapy Production:
Scalable Manufacturing: Hemostemix's patented Automated Cell Therapy System (ACTS) can scale from $12 million in annual revenue to $144 million monthly.
Each 10' x 10' clean room produces 2,880 ACP-01 therapies annually, which enables the Company to meet global demand.
2. Life-Saving Results with ACP-01:
Transforming Lives: ACP-01 has a 93.5% success rate in saving limbs from amputation for chronic limb-threatening ischemia (CLTI) patients, reducing the current five-year mortality rate from 60% to near zero.
3. Economic and Healthcare Benefits:
Hemostemix projects an 80% reduction in healthcare costs per patient due to ACP-01's ability to heal ulcers, relieve pain, and improve mobility.
4. Regulatory Pathway & Valuation:
Funded from cash flow, a multi-centre randomized Phase III clinical trial will further quantify ACP-01's efficacy.
To generate cash flow, the Company is announcing a number of trials, to look at how ACP-01 generates healing earlier in the disease processes of vascular dementia, peripheral arterial disease, ischemic cardiomyopathy, non ischemic dilated cardiomyoptathy, and angina.
5. Strategic Collaboration:
Hemostemix, in partnership with CytoImmune, Puerto Rico's Government, and leading healthcare professionals, is committed to advancing therapies for no-option patients with conditions such as vascular dementia, PAD, CLTI, and more.
Leveraging Puerto Rico's ACT 60 program, Hemostemix and CytoImmune plan to achieve the world's lowest R&D costs, with 50% reimbursement in cash for research conducted on the island of Puerto Rico.
"Our partnership with CytoImmune strengthens Hemostemix's ability to scale globally while delivering cost-effective, life-changing therapies to patients," stated Thomas Smeenk, President & CEO. "Puerto Rico's ACT 60 program and these investor summits allow us to demonstrate how Hemostemix is transforming regenerative medicine and healthcare economics."
About Hemostemix
Founded in 2003, Hemostemix is a clinical-stage biotechnology company recognized for its patented blood-based stem cell therapeutics platform. Hemostemix focuses on scaling angiogenic, neuronal, and cardiomyocyte cell precursors to treat no-option patients worldwide.
Stock Information: TSXV: HEM | OTC: HMTXF | FSE: 2VF0
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Program. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
